CorelineSoft Accelerates Global Remote Diagnosis Market Expansion Based on AI Technology

Coreline Soft announced on the 5th that it will expand its global remote diagnosis market penetration based on artificial intelligence (AI) software (SW) technology. After entering the remote diagnosis market through collaboration with global companies, Coreline Soft recently obtained international certifications such as the U.S. Health Insurance Portability and Accountability Act (HIPAA) and the European General Data Protection Regulation (GDPR). The company plans to drive performance growth by supplying additional AI SW based on its references and overseas certifications.

원본보기 아이콘

Coreline Soft entered the market last May by signing a strategic partnership with the UK remote diagnosis specialist company ‘DMC Healthcare’ based on its proprietary AI SW ‘AVIEW LCS Plus.’ DMC is a solution provider for the UK government-led lung cancer screening project and holds numerous references and local networks in the remote diagnosis field.

The remote diagnosis market is rapidly growing, centered on advanced countries such as the United States, the United Kingdom, and Japan. Following the COVID-19 pandemic, demand in related fields has surged, and governments worldwide are actively supporting remote diagnosis. Unlike traditional medical facility-oriented supply, remote diagnosis has a high potential to significantly expand the applicable patient group, and since AI SW sales fluctuate according to the number of patients, it has a substantial effect on performance contribution.

Coreline Soft plans to accelerate its global remote diagnosis market penetration based on accumulated references in major European countries and the U.S. market. The company explained that global remote diagnosis specialists are actively expanding market entry, and since its proprietary AI technology has been proven superior to the world’s number one company through recent international academic journals, new SW supply is expected to increase.

A Coreline Soft official said, “Advanced countries such as the UK are experiencing a surge in demand for remote diagnosis due to shortages of medical personnel and facilities, and unlike in Korea, the market is growing rapidly. As AI SW adoption accelerates overseas, we will expand market penetration based on AI SW approvals and remote diagnosis references covering most global markets, including the U.S. Food and Drug Administration (FDA) and European CE certification.”

He added, “In particular, since Coreline Soft’s flagship AI product recently demonstrated superior performance to Siemens’ top-tier diagnostic solution, the world’s number one company, in performance benchmarks, we expect supply to remote diagnosis companies alongside government-led projects to become full-scale. We will maximize AI SW-based performance growth by strengthening our entry into the remote diagnosis market, which has a high sales contribution.”

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.